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Abstract
2018 The British Pharmacological Society Cannabis is the most commonly used illicit substance worldwide
and the prevalence of users continues to increase. Over the last 2 decades, the world has seen significant
changes regarding cannabis for recreational use as well as application in its use as a therapeutic medicine. This
is likely to have influenced the decreasing perception of risks associated with the use of cannabis. Cannabis,
however, is not benign and, depending on the pattern of its use, can incur a range of harmful effects, which
have implications when prescribing medicinal cannabinoids for individuals. Based on research evidence from
recreational use of cannabis as well as the emerging data from trials of medicinal cannabis, we propose some
clinical domains that will need specific considerations when prescribing medicinal cannabis.
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Cannabis is the most commonly used illicit substance worldwide and the prevalence of users continues to increase. Over the last 2
decades, the world has seen significant changes regarding cannabis for recreational use as well as application in its use as a
therapeutic medicine. This is likely to have influenced the decreasing perception of risks associated with the use of cannabis.
Cannabis, however, is not benign and, depending on the pattern of its use, can incur a range of harmful effects, which have
implications when prescribing medicinal cannabinoids for individuals. Based on research evidence from recreational use of
cannabis as well as the emerging data from trials of medicinal cannabis, we propose some clinical domains that will need specific
considerations when prescribing medicinal cannabis.
Introduction
Cannabis is the most commonly used illicit substance world-
wide [1] and the prevalence of users continues to increase.
Over the last 2 decades, there have been significant changes
around the world regarding cannabis, including decriminal-
ization, and in some states or countries, legalization for recre-
ational use as well as access to cannabinoids for use as a
therapeutic medicine. Some, albeit not all, countries where
changes in relation to cannabis have occurred include
Canada, Australia, Israel, Uruguay, the USA, and some Euro-
pean and Scandinavian countries. This is likely to have influ-
enced the decreasing perception of risks associated with the
use of cannabis. Cannabis, however, is not benign and de-
pending on the pattern of its use, can incur a range of harmful
effects, which have implications when prescribing medicinal
cannabinoids for individuals.
Therapeutic indications for cannabis are assumed to
target the endocannabinoid system, which has receptors
(CB1 and CB2) involved in cognition, memory, analgesia,
psychomotricity, appetite and immune function. There are,
however, few data specifically on the efficacy of medicinal
cannabinoids for the various indications suggested to date.
There are even fewer data for a variety of specific populations
such as pregnancy, young people, elderly individuals with
complex comorbidities and those with mental health issues.
Substantial reliance on research evidence from recreational
use of cannabis is therefore required until robust data specif-
ically for medicinal cannabinoids become available.
A broad range of therapeutic effects of cannabinoids has
been suggested [2] and is currently the focus of much re-
search. Delta-9-tetrahydrocannabinol (THC) has been pro-
posed to be of benefit for chronic pain, nausea and vomiting
induced by chemotherapy, and in the reduction of spasms in
multiple sclerosis [2]. Cannabidiol (CBD) has antipsychotic,
anxiolytic and anticonvulsant properties and may reduce
Parkinsonian symptoms [2]. As the evidence base for clinical
indications for medicinal cannabinoids becomes clearer,
certain populations will require further special consideration:
Young people prescribed medicinal
cannabinoids
Cannabis is the most common illicit substance used by youth
in the western world. Evidence from this nonmedical use
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indicates that frequent use of cannabis during adolescence is
associated with a range of adverse psychosocial outcomes in
young adulthood, including other substance use and poorer
educational attainment and mental health [3]. Alterations
to the structure and function of the brain associated with ex-
posure to cannabis, particularly of high THC content, is
concerning for the developing brain [4–6]. Long-term medic-
inal cannabinoids may be contraindicated in this population
unless the condition is life limiting or severely debilitating.
There is some evidence of benefit in children and adolescents
for chemotherapy-induced nausea and vomiting and poten-
tially for epilepsy, but adverse effects are under-investigated
at present [7].
Elderly individuals
Elderly individuals may also be sensitive to the cognitive
effects of cannabis. There is growing concern that cannabis
use may be associated with dementia. Similarly, the cardio-
metabolic profile of medicinal cannabinoids needs clarifica-
tion, as this is especially important in the context of
complex comorbidities in elderly individuals who often have
a combination of cardiovascular disease, diabetes, liver or re-
nal impairment [1, 2].
Pregnancy
Placental transfer of cannabis to the fetus is known to occur,
although the exposure to cannabinoids is in smaller doses
compared to that of the mother. There are few data, however,
to indicate what effect cannabis specifically has on fetal de-
velopment, because of substantial confounding by tobacco
and other significant comorbid factors such as other sub-
stance use, mental health disorders, physical health condi-
tions and psychosocial factors. Notwithstanding, definitive
evidence of premature birth, growth restriction or a neonatal
withdrawal syndrome in babies or significant deficits in early
childhood development has not been reported for those ex-
posed in utero. With regard to breastfeeding, transfer of can-
nabinoids into breast milk does occur [8] and clinicians will
need to advise patients of the risks of exposing a child to a
lipid soluble drug known to affect brain development.
Driving
Cannabis has been associated with road traffic accidents and
fatal injuries [9]. The effects of cannabis on motor coordina-
tion, reaction time, judgement and tracking ability are well
documented, but a definition of a threshold serum cannabi-
noid level that would be expected to impair most people’s
driving capacity remains elusive, complicated further by find-
ings differing substantially between those recently exposed
to cannabis compared to cannabis-habituated individuals
[10]. It is therefore important for clinicians to inform patients
that driving is not recommended while taking medicinal
cannabinoids.
Mental health
Nonmedical cannabis use, and in particular THC, has been as-
sociated with depression, anxiety and psychosis [2]. This has
implications when cannabinoids are being considered for
therapeutic purposes. CBD, by contrast, has shown promis-
ing improvements in positive, negative and cognitive symp-
toms of schizophrenia with fewer extrapyramidal side
effects than antipsychotics currently available. CBD may
therefore serve as a useful alternative or adjunct medication
for psychosis and possibly a range of other mental health
conditions. Such hypotheses need to be tested with rigorous
clinical trials and robust evidence.
Addiction
Estimates suggest that over 180 million people use cannabis
for nonmedical, or recreational, purposes globally and that
approximately 13 million people are dependent on canna-
bis [11]. The number of cannabis users seeking treatment
for cannabis use disorder has increased over the past 2
decades in many countries such as Australia, Europe and
the USA. European figures show that the number of users
who started treatment for the first time due to cannabis-re-
lated problems has increased by >75% in 10 years [12]. This
increase in the demand for treatment may be linked to a
number of factors. The increased prevalence of cannabis
use, including heavy use, in the general population, in-
creased concentration of THC in street cannabis, and higher
prevalence rates of self-medication with cannabis. Given
this, and as occurs with all drugs with addiction liability,
the potential for misuse (defined as use that is not as pre-
scribed or use in individuals for whom there are contraindi-
cations to use), or diversion (defined as use by individuals
for whom the prescription was not intended) of medically
prescribed cannabinoids (especially THC) needs to be antic-
ipated and managed to reduce public health harm [13].
Future prevalence of dependence or addiction in those pre-
scribed medicinal cannabinoids is difficult to predict. The
current prescription opioid crisis in the western world, how-
ever, is a salient reminder that when prescribed widely, in
high-dose and long-term for chronic pain, rates of depen-
dence in the community could be high. Whether medicinal
cannabinoids have a role as substitution treatment in can-
nabis use disorder, analogous to opioid substitution treat-
ment for opioid dependence, or for other substance use
disorders, is unclear at present.
Administration of medicinal
cannabinoids
Data on cannabinoid components (e.g. THC:CBD ratio),
dosing and frequency regimen effective for various clinical
conditions are beginning to emerge. Cannabinoid effects
vary between products. Side-effects such as panic attacks,
short-term memory loss, tachycardia or hypertension may
occur even in recreational users but may be more severe in
those with complex conditions for which medicinal
Y. Bonomo et al.
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cannabinoids are prescribed, as the pharmacokinetics and
the pharmacodynamics are not well characterized in these
populations. Physicians also must decide on optimal mode
of administration; for example, smoking cannabis cannot
be recommended given the harmful products of combustion
[14]. The latter can be avoided through modes of adminis-
tration such as vaporisation, oromucosal sprays or sublin-
gual preparations (as in the case of nabiximols or Sativex).
These preparations also enable more immediate onset of
effect thus allowing titration of dose to optimal effect. Oral
formulations such as capsules and oils, less amenable to
titration, may also not be tolerated in the context of
profound nausea and vomiting characteristic of some condi-
tions. The use of transdermal patches may have promise in
clinical contexts where slower onset but longer duration of
action is required. Physicians must also monitor potential
drug interactions as the evidence emerges; for example, in
the trial of CBD in children with Dravet Syndrome, hepatic




In addition to the gradual emergence on the market of
approved pharmaceutical grade products containing canna-
binoids in specified amounts, many people continue to con-
sume illegal cannabinoid products of varying composition.
The latter can be harmful because of their unknown concen-
trations of cannabinoids, as well as inclusion of potentially
harmful contaminants and impurities [16]. In general, more
adverse effects might be expected from self-medication with
high potency cannabis products, particularly if used
frequently over the long-term.
Conclusion
As greater understanding about the therapeutic potential of
cannabinoids emerges, their relevance to public health is
also increasing. Use of unknown concentrations of
cannabinoids for therapeutic purposes can potentially be
harmful. Urgent clinical issues that need to be addressed
include:
• High-quality scientific evidence regarding the therapeutic
effects of cannabinoids for specific conditions through rig-
orous clinical trials is essential to inform appropriate use
of cannabis-derived substances by physicians.
• Reliable and comprehensive monitoring of cannabinoids
that are being used for therapeutic purposes in different
countries with oversight of the appropriate regulation
agency (e.g. Food and Drug Administration, European
Medicines Evaluation Agency, Anvisa, Therapeutic Goods
Administration or equivalent) to ensure that the cannabi-
noids available to patients are of high quality and safe to use
• Prompt communication of the findings of
pharmacovigilance activities to health professionals and
the community as they emerge to facilitate safe and effec-
tive translation for therapeutic purposes.
In accordance with the principles of evidence-based
medicine, this will promote the effective and safe use of
cannabinoids.
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